Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology (EPIDOCAVILH)

17. listopadu 2026 aktualizováno: Poitiers University Hospital

Pilot Study for the Evaluation of a City-hospital Pathway for Early Management of Acute Pain in Oncology

In France, the number of new cancer cases across all cancer types was estimated at 382,000 in 2018. The impact of pain on a patient's quality of life is profound, with physical consequences (insomnia, fatigue, loss of appetite), psychological effects (anxiety, depression, demoralization, attention deficit, memory disorders), and social repercussions.

Acute pain induced by cancer, when poorly managed, can lead to the development of secondary chronic pain syndrome. The French National Authority for Health (Haute Autorité de Santé, HAS) deplores the late referral of patients with chronic pain, which complicates treatment and limits opportunities for improvement. Cancer-related pain has become a chronic condition in 50% of patients, leading to anxiety-depressive syndromes as well as social consequences such as social isolation or difficulty returning to professional activity.

In France, the 2017 White Paper by the SFETD (French Society for the Study and Treatment of Pain) notes that, despite three successive Cancer Plans integrating supportive care into the comprehensive management of cancer patients, one in three patients does not receive analgesic treatment appropriate to the intensity of their pain. To prevent chronic pain, the HAS recently recommended early assessment of acute pain (within less than a week) with a high-quality city-hospital organization.

Přehled studie

Detailní popis

This study proposes a systematic care pathway for the evaluation and treatment of pain in patients experiencing pain symptoms at the time of cancer diagnosis or relapse. A multidimensional pain assessment consultation will be conducted within 48 hours, along with the implementation of appropriate treatment. The patient will receive therapeutic education for self-assessment of pain, enabling the general practitioner to adjust analgesic treatments on an outpatient basis. The relevance of this pathway lies in the systematic assessment of pain and close collaboration between the general practitioner and the hospital, coordinated by a pain specialist. The general practitioner, who has an in-depth knowledge of the patient, should remain the primary coordinator of the patient's health pathway.

Typ studie

Intervenční

Zápis (Odhadovaný)

30

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Patient ≥ 18 years old.
  • Consultation for treatment initiation (first-line or relapse) for gynecological, digestive, urological, or hematological cancer.
  • Patient experiencing pain related to a cancer pathology (pain numerical rating scale ≥ 1) for less than 3 months.
  • Patient receiving outpatient cancer treatment at the Châtellerault site of Poitiers University Hospital.
  • Patient declaring having a general practitioner.
  • Patient's general practitioner agreeing to participate in the study.
  • Patient covered by the French social Security system or through a third party.

Non-Inclusion Criteria:

  • Patient already receiving care for this pain from the reference pain center or supportive care team.
  • Patient unable to understand, write, or speak French.
  • Patient diagnosed with uncontrolled psychiatric disorders.
  • Patient with chronic pain unrelated to cancer.
  • Pain related to therapeutic procedures.
  • Patient residing in a medicalized facility.
  • Patient under enhanced protection, including: minors, pregnant or breastfeeding women, individuals deprived of liberty by judicial or administrative decision, individuals staying in a healthcare or social institution, adults under legal protection (guardianship, curatorship, or subordination), patients in emergency situations.
  • Patient with a significant impairment of general condition (ECOG-PS > 2, Eastern Cooperative Oncology Group Performance Status) or cognitive disorders.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Výzkum zdravotnických služeb
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Early management of acute pain

Day 0: Multidimensional pain assessment (MPA) consultation conducted by a qualified paramedical professional (QPP) within 48 hours following the oncology consultation. Multidimensional pain will be evaluated using the Brief Pain Inventory-Short Form (BPI-SF). The QPP transfers a report of this assessment to the general practitioner of the patient. Appropriate treatment of pain is implemented by the QPP.

Day 2: Consultation with the general practitioner. Based on the report send by the QPP at day 0 and with the self-administration of the BPI-SF fulfilled by the patient at day 2, the general practitioner adjusts pain-relieving treatments if necessary.

Day 7: MPA consultation conducted by the QPP who transfers a report of the BPI-SF assessment to the general practitioner. If the patient reports pain symptoms at day 7, then consultation with the general practitioner and MPA consultation are repeated ever week until resolution of pain symptoms.

Brief Pain Inventory-Short Form is performed twice every week (for the multidimensional pain assessment consultation and for the general practitioner consultation) until resolution of the pain symptoms or up to day 28 (end of the study).

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of eligible patients that provide a consent to participate
Časové okno: 1 day

Patient's acceptability will be assessed if ≥ 80% of the eligible patients provide a signed consent.

1 day
Proportion of general pactitioner that confirmed their participation
Časové okno: 2 days

General practitioner's acceptability will be assessed if ≥80% of the practitioners related to the eligible patients confirmed their participation.

2 days
Proportion of consultations with the general practitioner performed
Časové okno: 28 days

Completion of consultations with the general practitioner will be assessed if ≥ 80% of the consultations with the general practitioner recommended by the pathway are completed.

28 days
Proportion of consultations at the hospital performed
Časové okno: 28 days

Completion of consultations at the hospital will be assessed if ≥ 80% of the consultations at the hospital recommended by the pathway are completed.

28 days

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in pain severity after 28 days
Časové okno: 28 days

Pain severity is assessed using the dimension "pain severity" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain severity is defined as the difference of the two scores assessed at day 0 and at day 28. Pain severity score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in pain interference after 28 days
Časové okno: 28 days

Pain interference is assessed using the dimension "pain interference" of the Brief Pain Inventory-Short Form (BPI-SF). Change in pain interference is defined as the difference of the two scores assessed at day 0 and at day 28. Pain interference score ranges from 0 (no pain) to 10 (severe pain).

28 days
Change in quality of life after 28 days
Časové okno: 28 days

Quality of life is assessed using the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer, Quality of Life Core Questionnaire). Change in quality of life is defined as the difference of the global quality of life scores assessed at day 0 and at day 28. Quality of life score ranges from 0 (worst quality of life) to 100 (best quality of life).

28 days
Proportion of patients requiring a specific pain management
Časové okno: 28 days

Specific pain management includes: hospitalization due to the pain, referral to a pain management center, or referral to a mobile palliative care team.

28 days
Global satisfaction of the patients
Časové okno: 28 days

Satisfaction of the patient will be assessed using a 5-point Likert scale (0 anchored with "not satisfied at all" and 4 anchored with "very satisfied")

28 days
Proportion of patients with a modified prescription by the general practitioner for analgesics treatments
Časové okno: 28 days

The proportion of patients with a new analgesic treatment added or with a dose escalation or a dose reduction or a therapeutic switch

28 days

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. ledna 2027

Primární dokončení (Odhadovaný)

31. ledna 2028

Dokončení studie (Odhadovaný)

31. prosince 2028

Termíny zápisu do studia

První předloženo

20. října 2026

První předloženo, které splnilo kritéria kontroly kvality

17. listopadu 2026

První zveřejněno (Aktuální)

19. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

19. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit